Reviewers describe the support team as responsive, professional, and genuinely helpful
Rather than buying several small kits, users deal with one consistent package
TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
Endocrinology 151 (4), 14731486
[8] The rise of the Ozempic microdosing trend Despite Ozempics intended once-weekly dosing, an online subculture has emerged promoting microdosing of Ozempic and similar GLP-1 drugs as a do-it-yourself weight-loss hack
As shortages of brand-name GLP-1 medications begin to ease, regulators are increasing scrutiny on these platforms to ensure patient safety and compliance, signaling a broader crackdown on unapproved or gray-market weight-loss treatments